David Dadiomov, PharmD, BCPP
Faculty Directory

David DadiomovPharmD, BCPP

David DadiomovPharmD, BCPP

Clinical Assistant Professor of Pharmacy Practice | Clinical Coordinator | Whole Person Care Clinical Pharmacy Program

Titus Family Department of Clinical Pharmacy

David Dadiomov, PharmD, BCPP, is a clinical assistant professor of pharmacy practice in the Titus Family Department of Clinical Pharmacy.

He came to the USC School of Pharmacy from Miami, where he served as assistant professor at Larkin University College of Pharmacy, coordinating and teaching courses on the pathophysiology and treatment of various diseases and disorders. He also served as clinical psychiatric specialist at Larkin Community Hospital.

He received his PharmD from the University of Michigan College of Pharmacy. He completed his PGY1 Pharmacy Residency at Michigan Medicine, and his PGY2 Psychiatric Pharmacy Residency at University of California, San Diego, Health. He holds board certification in psychiatric pharmacy.

Dadiomov serves as the clinical coordinator for the Whole Person Care Clinical Pharmacy Program. This collaboration with the L.A. County Department of Health Services, Department of Mental Health and Correctional Health Services aims to improve access and quality of care to Los Angeles County’s most marginalized patients, including those experiencing homelessness, re-entry, mental health, substance use and medical high-risk patients.

    Areas of Expertise

    • Psychoactive Substances
    • Substance Use Disorders
    • Psychiatric Disorders
    • Pharmacy Practice
    • Psychopharmacology
    • Education

      University of Michigan College of Pharmacy

      PharmD

      Michigan Medicine

      PGY1

      UC San Diego Health

      PGY2

    • Links
    • Selected Articles

      Safety of Repeated Administration of Parenteral Ketamine for Depression

      Pharmaceuticals
      David Feifel, David Dadiomov, Kelly Lee

      The objective of this study was to investigate the safety of repeated parenteral ketamine for depression. An electronic survey inquiring about the frequency of adverse events was distributed to providers of parenteral ketamine for depression. In addition, the investigators conducted a search of published studies describing six or more repeated parenteral ketamine treatments administered to individuals for depression, and extracted reported adverse events. The survey was sent to 69 providers, of which 36 responded (52% response rate); after eliminating those that were incomplete, 27 were included in the analysis. The providers in the analysis collectively reported treating 6630 patients with parenteral ketamine for depression, one-third of whom received more than 10 treatments. Only 0.7% of patients experienced an adverse effect that required discontinuation of ketamine. Psychological distress during the treatment was the most frequent cause. Other adverse events were extremely rare (such as bladder dysfunction (0.1%), cognitive decline (0.03%) and psychotic symptoms (0.03%)). Among the 20 published reports of repeated parenteral ketamine treatments, rates of significant adverse events resulting in discontinuation were low (1.2%). The rate of adverse effects reported in the survey and the published literature is low, and suggests that long-term treatment of depression with ketamine is reasonably safe.

      Read More

      Chapter 3: Laboratory Testing for Substance Use Disorders

      Absolute Addiction Psychiatry Review
      David Dadiomov

      This book serves as a tool for general psychiatrists, medical students, residents, and fellows looking for a clinically relevant and high-yield overview of addiction psychiatry in preparation for their board exams – or for everyday clinical practice. Written by expert educators in addiction psychiatry, the text is organized by substances misused and populations affected. This book serves as both a primary learning tool for those new to the field, as well as a reference for those working in addiction treatment. Each chapter begins with summaries of high yield clinical pearls, followed by general information including treatment, and then ends with accompanying board-style review questions. The scope includes understanding substances of misuse and substance use disorders (SUDs), how to evaluate, diagnose, and monitor SUDs, how to treat SUDs both pharmacologically and behaviorally, and critical information for specific populations of patients.

      Read More

      Therapeutic Drug Monitoring of Antipsychotics

      Current Psychiatry
      David Dadiomov

      Savvy Psychopharmacology Column in Current Psychiatry

      Read More

      Dissociating the Clinical Role and Economic Value of Intranasal Esketamine

      Journal of Managed Care & Specialty Pharmacy
      David Dadiomov

      Perspective on Value: Dissociating the Clinical Role and Economic Value of Intranasal Esketamine

      Read More

      The effects of ketamine on suicidality across various formulations and study settings

      Mental Health Clinician
      David Dadiomov and Kelly Lee

      2019 Suicidality and self-injurious behavior afflict patients with a wide variety of psychiatric illnesses. Currently, there are few pharmacologic treatments for suicidality and self-injurious behavior and none that treat these conditions emergently. Recently, ketamine has demonstrated efficacy in treating both depression and acute suicidal ideation. An increasing usage of ketamine, of a variety of formulations, has been studied for these indications. This article reviews the evidence for use of ketamine in self-injurious behavior and suicidality.

      Read More

      Using the LACE Score as a Predictor of Clinical Outcomes in Patients Referred for Inpatient Palliative Care Consultation: A Single-Center Experience

      American Journal of Hospice and Palliative Medicine
      David Dadiomov, Patricia Keefer, and Michael A. Smith

      2018 Readmissions and death for palliative care patients are common and costly outcomes for hospitals, patients, and/or caregivers. Predicting which patients are likely to be readmitted or die within 30 days would help allocate resources and aid in patient disposition planning. Few factors have been strongly correlated with predicting which patients will be readmitted or die within 30 days of hospital discharge. The LACE (Length of Stay, Acuity of admission, Charlson comorbidity index, Emergency department use) score has been validated in medical/surgical patients; however, it has not been evaluated in the palliative care population.

      Read More

    • Selected Media Appearances

      Dadiomov Joins Faculty

      USC News | 06/10/2019

      David Dadiomov, PharmD, BCPP, has joined the faculty of the Titus Department of Clinical Pharmacy as clinical assistant professor of pharmacy practice.

      Read More